Aclarion Inc (ACON)vsAstraZeneca PLC (AZN)
ACON
Aclarion Inc
$3.57
+1.13%
HEALTHCARE · Cap: $8.27M
AZN
AstraZeneca PLC
$185.95
-0.79%
HEALTHCARE · Cap: $282.69B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 77605189% more annual revenue ($60.44B vs $77,880). AZN leads profitability with a 17.2% profit margin vs 0.0%. AZN earns a higher WallStSmart Score of 64/100 (C+).
ACON
Avoid29
out of 100
Grade: F
AZN
Buy64
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for ACON.
Margin of Safety
+8.2%
Fair Value
$194.77
Current Price
$185.95
$8.82 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Mega-cap, among the largest globally
Every $100 of equity generates 22 in profit
Strong operational efficiency at 27.9%
Generating 1.8B in free cash flow
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Moderate valuation
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : ACON
The strongest argument for ACON centers on Price/Book. Revenue growth of 11.3% demonstrates continued momentum.
Bull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.2% and operating margin at 27.9%. Revenue growth of 12.5% demonstrates continued momentum.
Bear Case : ACON
The primary concerns for ACON are EPS Growth, Market Cap, Profit Margin.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, Altman Z-Score.
Key Dynamics to Monitor
ACON profiles as a value stock while AZN is a mature play — different risk/reward profiles.
ACON carries more volatility with a beta of 1.19 — expect wider price swings.
AZN is growing revenue faster at 12.5% — sustainability is the question.
AZN generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (64/100 vs 29/100), backed by strong 17.2% margins and 12.5% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Aclarion Inc
HEALTHCARE · HEALTH INFORMATION SERVICES · USA
Aclarion Inc (ACON) is a pioneering healthcare technology company that specializes in non-invasive diagnostics, focusing on musculoskeletal conditions through innovative imaging and advanced data analytics. By harnessing machine learning, Aclarion provides healthcare professionals with actionable insights that enhance clinical outcomes while optimizing costs within treatment pathways. Positioned at the vanguard of the digital health transformation, Aclarion is poised to meet the increasing demand for effective diagnostic solutions, significantly enhancing the standard of patient care in an evolving healthcare landscape. Its commitment to improving patient management establishes Aclarion as a key player in the future of healthcare delivery.
Visit Website →AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Compare with Other HEALTH INFORMATION SERVICES Stocks
Want to dig deeper into these stocks?